Allogeneic Islet Cell Therapy Restores Insulin Production in Type 1 Diabetes Patients
A phase 1/2 study of Vertex Pharmaceuticals’ investigational therapy zimislecel (VX‑880) demonstrated that all twelve participants with type 1 diabetes and impaired hypoglycemic awareness regained endogenous insulin secretion, measured by C‑peptide levels. This breakthrough shows that transplanting donor‑derived…
Continue reading Allogeneic Islet Cell Therapy Restores Insulin Production in Type 1 Diabetes Patients